SAFETYLIT WEEKLY UPDATE

We compile citations and summaries of about 400 new articles every week.
RSS Feed

HELP: Tutorials | FAQ
CONTACT US: Contact info

Search Results

Journal Article

Citation

Westergren T, Narum S, Klemp M. BMJ Open 2020; 10(7): e036412.

Copyright

(Copyright © 2020, BMJ Publishing Group)

DOI

10.1136/bmjopen-2019-036412

PMID

32690742

PMCID

PMC7375629

Abstract

OBJECTIVES: To analyse to what extent clinical practice guidelines on drug treatment of depression in children and adolescents mention the risk of adverse effects, to characterise the citations in the guidelines and to assess to what extent data from a major study (Treatment for Adolescents With Depression Study, TADS) was used as basis for information about adverse effects.
DESIGN: Systematic review of clinical guidelines and clinical decision support tools.
DATA SOURCES: PubMed, EMBASE, guideline collections, Health libraries.
ELIGIBILITY CRITERIA: We included national guidelines on depression in children and adolescents from European and/or English-speaking countries, published in English, German, French or any Scandinavian language since 2008. We also included well-known, international clinical decision support tools.
DATA EXTRACTION AND SYNTHESIS: Guidelines were examined by all authors to identify and classify information on adverse effects. Citations for statements on adverse effects were extracted and classified by category. The extent of citations about suicidality risk versus other adverse effects was assessed.
RESULTS: 19 guidelines were assessed. All guidelines discussed risk of suicidal behaviour connected with use of antidepressants. Most guidelines mentioned some other psychiatric adverse effects. Several guidelines did not include information on well-known and common somatic adverse effects. Most references concerned risk of suicidality. Adverse effects identified in underlying studies were not always presented. The TADS study was referred to, directly or indirectly, by 18/19 guidelines, but some only referred to TADS with regard to suicidality without citing the study's findings of somatic adverse effects. No guideline commented on the lack of long-term adverse effects data from TADS.
CONCLUSIONS: Guidelines for treatment of depression in children and adolescents vary widely regarding information on adverse effects. Many guidelines do not provide information on common somatic adverse effects. There is no consensus as to what extent risks of adverse effects connected with use of antidepressants should be described in guidelines.


Language: en

Keywords

Humans; Child; Adolescent; Depression; Suicidal Ideation; psychiatry; Antidepressive Agents; adverse events; protocols & guidelines; clinical pharmacology

NEW SEARCH


All SafetyLit records are available for automatic download to Zotero & Mendeley
Print